BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 29036248)

  • 1. Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis.
    Bagel J; Nelson E; Keegan BR
    J Drugs Dermatol; 2017 Oct; 16(10):957-962. PubMed ID: 29036248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Home Narrowband Ultraviolet B Phototherapy for Photoresponsive Skin Conditions: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(12):1-134. PubMed ID: 33240453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial.
    Fiorillo L; Becker E; de Lucas R; Belloni-Fortina A; Armesto S; Elewski B; Maes P; Oberoi RK; Paris M; Zhang W; Zhang Z; Arkin L
    J Am Acad Dermatol; 2024 Jun; 90(6):1232-1239. PubMed ID: 38266683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tazarotene gel with narrow-band UVB phototherapy: a synergistic combination in psoriasis.
    Dayal S; Kaura R; Sahu P; Jain VK
    An Bras Dermatol; 2018 Jun; 93(3):385-390. PubMed ID: 29924221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TWEAK levels in psoriatic patients treated with narrowband ultraviolet B and methotrexate.
    Hegazy EM; El Taieb MA; Ibrahim HM; Rageh EM; Ahmed NM; Ibrahim AK; Younis AM; Ali MA
    J Cosmet Dermatol; 2024 May; 23(5):1905-1911. PubMed ID: 38299446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, tolerability and patient's satisfaction for the treatment of moderate to severe plaque psoriasis with apremilast in the real-life setting of Campania region, Italy.
    Licata G; Tancredi V; Gambardella A; Megna M; Fabbrocini G; Raimondo A; Lembo S; Ligrone L; Cusano F; Argenziano G
    Ital J Dermatol Venerol; 2023 Dec; 158(6):452-456. PubMed ID: 37721774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Quality of Life in Patients with Psoriasis Receiving Apremilast: Real-World Data from the Netherlands.
    van den Reek JMPA; van der Leest RJT; Thomas SE; Prevoo R; Plantenga ME; de Jong EMGJ
    Adv Ther; 2024 Apr; 41(4):1594-1605. PubMed ID: 38402373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost per response analysis of deucravacitinib versus apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States.
    Park SH; Lambton M; Schmier J; Hovland S; Wittstock K; Patel V
    J Dermatolog Treat; 2024 Dec; 35(1):2366503. PubMed ID: 38914425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Apremilast Use for Treatment of Plaque Psoriasis in Italy: Patient Perspective, Characteristics, and Clinical Outcomes from the DARWIN Study.
    Giofrè C; Fabbrocini G; Potenza C; Tiberio R; Gisondi P; Marasca C; Nuzzo CMA; Benincasa E; Bianchi L;
    Adv Ther; 2023 Jul; 40(7):3021-3037. PubMed ID: 37171752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D Receptor Expression in Chronic Plaque Psoriasis Before and After Narrowband Ultraviolet B Phototherapy.
    Elgarhy LH; Eltatawy RA; Rizk O; Ismail M
    J Cutan Aesthet Surg; 2023; 16(2):128-133. PubMed ID: 37554687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate did not add skin cancer risk in patients with psoriasis receiving narrowband ultraviolet B phototherapy: a nationwide retrospective cohort study.
    Chao CH; Wu CY; Chou FL; Chen YJ
    Clin Exp Dermatol; 2024 Apr; 49(5):459-465. PubMed ID: 38056487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Throughput RNA Sequencing Reveals the Effect of NB-UVB Phototherapy on Major Inflammatory Molecules of Lesional Psoriasis.
    Vacharanukrauh P; Meephansan J; Tangtanatakul P; Soonthornchai W; Wongpiyabovorn J; Serirat O; Komine M
    Psoriasis (Auckl); 2021; 11():133-149. PubMed ID: 34858799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative evaluation of efficacy and tolerability of apremilast and methotrexate in patients of moderate-to-severe palmoplantar psoriasis: A randomized, parallel, open-label clinical trial.
    Wagh M; Mukhi J; Sontakke S; Dhok A; Turankar A; Kalikar M
    Indian J Pharmacol; 2023; 55(6):356-362. PubMed ID: 38174531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of narrowband ultraviolet B monotherapy versus combination therapy with systemic agents in patients with early-stage mycosis fungoides and the association with plaque lesions.
    Qin Y; Lin Y; Chen Z; Zhang Q; Li Y; Wen Y; Tu P; Gao P; Wang Y
    J Evid Based Med; 2024 Jun; ():. PubMed ID: 38898743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Narrowband Ultraviolet Light in Chronic Kidney Disease-Associated Pruritus.
    Shabi I; Aboudar Z; Sidki M; Amal S; Hocar O; Aboudourib M; Hamouche N; Chettati M; Fadili W; Laouad I
    Cureus; 2024 Jan; 16(1):e53340. PubMed ID: 38435935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NB-UVB irradiation attenuates inflammatory response in psoriasis.
    Ye J; Huang H; Luo G; Yin L; Li B; Chen S; Li H; Yang Y; Yang X
    Dermatol Ther; 2020 Jul; 33(4):e13626. PubMed ID: 32431049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elucidating the NB-UVB mechanism by comparing transcriptome alteration on the edge and center of psoriatic plaques.
    Boonpethkaew S; Meephansan J; Charoensuksira S; Jumlongpim O; Tangtanatakul P; Wongpiyabovorn J; Komine M; Morita A
    Sci Rep; 2023 Mar; 13(1):4384. PubMed ID: 36928592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey.
    Bhutani T; Jayade S; Rege S; Penton H; Patel V; Kalirai S; Wolin D; Boyle K; Seigel L
    J Dermatolog Treat; 2024 Dec; 35(1):2366532. PubMed ID: 38914422
    [No Abstract]   [Full Text] [Related]  

  • 19. A Comparative Study of the Efficacy of Methotrexate versus Methotrexate with Apremilast in Moderate to Severe Chronic Plaque Psoriasis.
    Srivastava D; Krishna A; David A
    Indian J Dermatol; 2023; 68(4):393-398. PubMed ID: 37822410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lesion area reduction and the amelioration of anxiety and depression states in psoriasis patients: A prospective clinical study.
    Yu Y; Zhou J; Huang D; Zhong X; Kong L; Ding Y; Bi X; Deng H; Chen J; Gu J; Lu J; Shi Y
    J Affect Disord; 2024 Jan; 344():335-338. PubMed ID: 37827263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.